| INTRODUCTION
Atrial fibrillation is a common cardiac dysrhythmia with increasing prevalence in the aging population. It remains one of the strongest risk factors for stroke and a major cause of cardiovascular morbidity worldwide (January et al., 2014; Kirchhof et al., 2016) . Moreover, this arrhythmia is a frequent cause of hospital presentations and admissions, and is commonly encountered on daily basis especially in the emergency departments (Go et al., 2001; Friberg, Buch, Scharling, Gadsbøll, & Jensen, 2003) . Conversion of recent onset atrial fibrillation into normal sinus rhythm (NSR) is essentially important for reducing the risk of hemodynamic instability, atrial remodeling, and the rate of hospitalizations (Conde & Baranchuk, 2014) . Conversion into NSR can be achieved either pharmacologically or by direct-current (DC) electrical cardioversion. While DC electrical cardioversion is more effective and restores NSR instantaneously, it necessitates the use of general anesthesia. Also, it can be associated with psychological stress for the patient along with multiple adverse events such as skin burns, heart block, and pacemaker malfunction (if present) Hanley, Robinson, & Kowey, 2016; Van Gelder, Tuinenburg, Schoonderwoerd, Tieleman, & Crijns, 1999; Conde, Lalor, Rodriguez, Elissamburu, & Marcelo, 2013) .
Although antiarrhythmic drug therapy is a cornerstone in the treatment of cardiac arrhythmias, the development of new antiarrhythmics has remained slow despite substantial efforts given. This is most likely due to our limited understanding of the complex interplay between various ionic currents and their definitive role in arrhythmogenesis (Hanley et al., 2016; Kumar & Zimetbaum, 2013) . Currently available antiarrhythmic drugs are limited by incomplete efficacy for maintaining NSR along with their extensive side effects profiles such as life-threatening ventricular arrhythmias and extracardiac toxicities (Camm, 2012; Tsuji & Dobrev, 2013) .
Vernakalant is the first antiarrhythmic drug with selectively preferential effects on the atrial tissue. This atrial-selectivity causes a prolongation in the effective refractory period of the atria with minimal effects on the ventricles (Tsuji & Dobrev, 2013; Dorian et al., 2007; Dobrev, Hamad, & Kirkpatrick, 2010) . Vernakalant is hepatically metabolized by cytochrome P450 (CYP 2D6) with a half-life of approximately 3 hr, and can reach up to 8.5 hr in poor metabolizers (Savelieva, Studies included in quantitative synthesis (meta-analysis) (n = 9)
2009). The mean plasma concentration of vernakalant peaks at the end of its ten-minutes infusion and decreases abruptly afterwards.
No dose adjustment for age, gender, or renal function is required.
Moreover, it is unlikely for vernakalant to cause any major drug-drug interactions given its rapid distribution, short half-life and lack of significant effect on CYP3A4 (Savelieva et al., 2014; Mao et al., 2009 ).
| METHODS

| Search strategy
In this meta-analysis, all prospective randomized controlled trials (RCTs)
testing the efficacy and safety of vernakalant versus a control drug for conversion of recent-onset atrial fibrillation or atrial flutter into NSR were identified. An online database search using Cochrane Central
Register of Controlled Trials and PubMed/MEDLINE for all relevant trials published since 1993 onward till the date of last search: July 1, 2017
was conducted. English language restriction was applied to the search.
Keywords and MeSH terms used included: "atrial fibrillation," "atrial flutter," "vernakalant," "RSD1235," "clinical trials," and "randomized controlled trials." Meeting abstracts or other gray literature weren't included. In addition, a manual search of secondary sources which included reference lists of initially reviewed articles was performed.
| Study selection
Abstracts of trials meeting the following inclusion criteria were considered for review: (i) randomized controlled trial; (ii) studies that compared vernakalant versus a control drug; (iii) patient population with atrial fibrillation or atrial flutter. In addition, full-text articles of abstracts that were unclear with respect to meeting the inclusion criteria were retrieved for further analysis. A PRISMA (Moher, Liberati, Tetzlaff, & Altman, 2009) flow diagram of the trials' selection is illustrated in Figure 1 . Nine prospective randomized controlled trials were included in this meta-analysis: The CRAFT trial (Roy et al., 2004) ; the ACT I trial ; the ACT II trial (Kowey et al., 2009) ; the ACT III trial (Pratt et al., 2010) ; the AVRO trial (Camm et al., 2011) ; the Scene II trial ; Simon et al.
trial (Simon et al., 2016) ; Beatch and Mangal trial (Beatch & Mangal, 2016) ; and the Asia-Pacific trial (Beatch, Bhirangi, Juul-Moller, & Rustige, 2016) .
| Data abstraction
Dichotomous data type was extracted, i.e. the number of events and participants in the experimental and the control groups were identified. Relevant baseline characteristics of patients were extracted and presented in Table 1 .
| Study outcome
The primary outcome of interest in this meta-analysis was the pro- (13) 68 (7) 62 (11) 63 (11) 68 (11) 57 (15) 62 (13) 60 ( (20) 129 (80) 31 (12) 52 (22) NR 7 (7) 30 (15) 11 (10) No. CHF (%) Excluded 50 (15) 51 (32) 52 (20) 46 ( 
| Data synthesis and analysis
A meta-analysis was conducted from the extracted data using Review
Manager (RevMan, version 5.4; Cochrane). Pooled risk ratios (RRs) were generated along with their 95% confidence intervals (CIs). To account for between-studies heterogeneity, the random effects model was used.
A p value of <.05 was predefined to indicate statistical significance.
Moreover, heterogeneity was assessed using chi-square test and the I 2 test, with considerable heterogeneity defined as I 2 > 50%.
| RESULTS
As summarized in Figure 1 , and after removing duplicates, the search yielded 174 potentially pertinent articles. Of them, 9 prospective randomized controlled trials were identified and included in the meta-analysis; 
| DISCUSSION
Vernakalant is a relatively new antiarrhythmic agent with predominant properties on atrial electrophysiology. It has been used in many European countries for pharmacological cardioversion of new-onset atrial fibrillation. At physiological heart rates, the block of atrial sodium (Na + ) channels by vernakalant is relatively weak due to rapid unbinding kinetics from the channel. While at higher heart rates, its affinity for activated Na + channels becomes greater (Tsuji & Dobrev, 2013; Savelieva et al., 2014; Fedida, 2007) . Hence, effects on Na + channels are rate and voltage dependent, i.e. it will likely exert an enhanced inhibitory effect at rapid rates and depolarized potentials as in the fibrillating atria (Conde & Baranchuk, 2014) . Moreover, vernakalant inhibits the early activating potassium (K + ) channels I Kur and I K,ACh . These currents are specific to the atrium and are the ones responsible for prolongation of the atrial refractory period (Fedida, 2007; Fedida et al., 2005; Camm, 2014) Consequently, this atrial selectivity along with the minimal effects on the ventricles explain the low proarrhythmic risk for torsades de pointes (TdP) arrhythmia with vernakalant use (Dobrev et al., 2010; Dorian et al., 2007) . (Camm, 2014) .
According to this meta-analysis, vernakalant was effective in patients with recent-onset atrial fibrillation. However, for atrial flutter patients it wasn't. The explanation for its lack of effect is unclear yet. It is possible that more selective and potent blockade of the potassium current, especially I Kr , as seen with ibutilide or dofetilide, is required for effective conversion of atrial flutter into NSR .
Moreover, this lack of effect could be related to the lower atrial rate with atrial flutter compared to atrial fibrillation. It is also interesting to observe that atrial flutter has been reported after vernakalant infusion. Although most of the reported cases where self-limited, some required electrical cardioversion (Roy et al., 2004; Simon et al., 2016; Beatch & Mangal, 2016; Cosin-Sales et al., 2016; .
Nevertheless, there are few described cases of atrial flutter with 1:1 atrioventricular (AV) conduction after administration of vernakalant for atrial fibrillation (Franzini, Muller-Burri, & Shah, 2014; de Riva-Silva et al., 2012) . The mechanism behind this is also uncertain. It is possible that slowing of atrial conduction due to Na + channels blocking could have favored the conversion into atrial flutter.
With respect to safety issues, vernakalant has been mainly evaluated within hours to days from drug administration. The most common adverse events were mild to moderate in nature and included dysgeusia, sneezing, and paresthesia, which are probably secondary to Na + channel blockade in the central nervous system (Savelieva et al., 2014) . Currently, the drug is still not approved for use in the United States as the FDA continues to have further questions about the safety of the drug (Camm, 2014) . The FDA had concerns about drug-induced hypotension as well as safety issues in patients with heart failure and acute coronary syndromes. Furthermore, the FDA requested another large trial to be conducted in 2008 to address the drug's safety. The ACT 5 trial was designed for this purpose; however, it was terminated early after a case of cardiogenic shock in a patient who received vernakalant (Camm, 2014) .
In the included trials of this meta-analysis, the reported adverse events were not homogenous across the studies. Moreover, not all the trials specified exactly the adverse events of interest.
In addition, none of the included trials specified whether there are certain subgroups of patients who are at higher risk for developing adverse events. For example, it was unclear whether the adverse events happened mainly in heart failure patients or not, especially events of hypotension. Thus, more safety data needs to be collected while taking into consideration the variable comorbidity profiles in the population.
